165 related articles for article (PubMed ID: 21217087)
1. Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.
Bessonova L; Taylor TH; Mehta RS; Zell JA; Anton-Culver H
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):389-96. PubMed ID: 21217087
[TBL] [Abstract][Full Text] [Related]
2. Second primary breast cancer occurrence according to hormone receptor status.
Kurian AW; McClure LA; John EM; Horn-Ross PL; Ford JM; Clarke CA
J Natl Cancer Inst; 2009 Aug; 101(15):1058-65. PubMed ID: 19590058
[TBL] [Abstract][Full Text] [Related]
3. Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.
Rusner C; Wolf K; Bandemer-Greulich U; Engel J; Stegmaier C; Holleczek B; Schubert-Fritschle G; Tillack A; Stang A
Breast Cancer Res; 2014 Oct; 16(5):452. PubMed ID: 25277819
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
[TBL] [Abstract][Full Text] [Related]
5. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
6. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.
Tao L; Chu L; Wang LI; Moy L; Brammer M; Song C; Green M; Kurian AW; Gomez SL; Clarke CA
Cancer Causes Control; 2016 Sep; 27(9):1127-38. PubMed ID: 27496200
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of breast cancer subtypes in adolescent and young adult women.
Keegan TH; DeRouen MC; Press DJ; Kurian AW; Clarke CA
Breast Cancer Res; 2012 Mar; 14(2):R55. PubMed ID: 22452927
[TBL] [Abstract][Full Text] [Related]
8. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
Brown M; Bauer K; Pare M
Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.
Sughayer MA; Al-Khawaja MM; Massarweh S; Al-Masri M
Pathol Oncol Res; 2006; 12(2):83-6. PubMed ID: 16799708
[TBL] [Abstract][Full Text] [Related]
10. Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010.
Parise CA; Caggiano V
BMC Cancer; 2013 Oct; 13():449. PubMed ID: 24083624
[TBL] [Abstract][Full Text] [Related]
11. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
12. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
[TBL] [Abstract][Full Text] [Related]
13. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011).
Sineshaw HM; Gaudet M; Ward EM; Flanders WD; Desantis C; Lin CC; Jemal A
Breast Cancer Res Treat; 2014 Jun; 145(3):753-63. PubMed ID: 24794028
[TBL] [Abstract][Full Text] [Related]
14. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
15. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
16. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
17. Hypothesized role of pregnancy hormones on HER2+ breast tumor development.
Cruz GI; Martínez ME; Natarajan L; Wertheim BC; Gago-Dominguez M; Bondy M; Daneri-Navarro A; Meza-Montenegro MM; Gutierrez-Millan LE; Brewster A; Schedin P; Komenaka IK; Castelao JE; Carracedo A; Redondo CM; Thompson PA
Breast Cancer Res Treat; 2013 Jan; 137(1):237-46. PubMed ID: 23135573
[TBL] [Abstract][Full Text] [Related]
18. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
19. HER2 status and disparities in luminal breast cancers.
Holowatyj AN; Ruterbusch JJ; Ratnam M; Gorski DH; Cote ML
Cancer Med; 2016 Aug; 5(8):2109-16. PubMed ID: 27250116
[TBL] [Abstract][Full Text] [Related]
20. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
